Effectiveness and safety of a novel dexamethasone mouthwash formulation in managing stomatitis in cancer patients
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Fernández-Sala, Xènia
- dc.contributor.author Barceló-Vidal, Jaime
- dc.contributor.author Tusquets, Ignasi
- dc.contributor.author Conde Estévez, David
- dc.date.accessioned 2022-06-07T06:38:27Z
- dc.date.available 2022-06-07T06:38:27Z
- dc.date.issued 2020
- dc.description.abstract Objective: To present a new dexamethasone mouthwash formulation and analyze its effectiveness and safety among patients receiving stomatitis-producing antineoplastic agents. Method: Prospective observational study conducted in a university hospital between March 2017 and November 2019. Consecutive patients starting everolimus were enrolled. Patients were instructed to rinse dexamethasone mouthwash formulation twice daily until discontinuation of everolimus. A second cohort of patients with existing stomatitis induced by high probability of producing stomatitis chemotherapy therapies was also recruited to assess treatment effectiveness. Effectiveness and safety of dexamethasone mouthwash formulation was assessed. Results: Dexamethasone mouthwash formulation was prescribed in nine patients as prophylaxis. Six patients were diagnosed with breast cancer, two with neuroendocrine tumor and one with renal cell carcinoma. Four patients developed mild stomatitis (grade 1-2) and three patients discontinued everolimus due to other treatment-related adverse events. In addition, dexamethasone mouthwash formulation was prescribed as treatment in five patients with existing stomatitis. All patients achieved a significant reduction in the severity of stomatitis after starting the dexamethasone mouthwash formulation. In both cohorts, dexamethasone mouthwash formulation was well tolerated and neither dose reduction nor discontinuation related to stomatitis was required. Conclusions: Dexamethasone mouthwash formulation could be considered as a suitable alternative for stomatitis management.
- dc.format.mimetype application/pdf
- dc.identifier.citation Fernández-Sala X, Barceló-Vidal J, Tusquets I, Conde-Estévez D. Effectiveness and safety of a novel dexamethasone mouthwash formulation in managing stomatitis in cancer patients. Farm Hosp. 2020 Nov 14; 45(1): 41-4. DOI: 10.7399/fh.11460
- dc.identifier.doi http://dx.doi.org/10.7399/fh.11460
- dc.identifier.issn 1130-6343
- dc.identifier.uri http://hdl.handle.net/10230/53391
- dc.language.iso eng
- dc.publisher Sociedad Española de Farmacia Hospitalaria
- dc.rights Los artículos publicados en esta revista se distribuyen con la licencia Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. http://creativecommons.org/licenses/by-nc-sa/4.0/
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc-sa/4.0/
- dc.subject.other Vitamina D
- dc.subject.other Mortalitat
- dc.subject.other Malalts
- dc.subject.other COVID-19 (Malaltia)
- dc.title Effectiveness and safety of a novel dexamethasone mouthwash formulation in managing stomatitis in cancer patients
- dc.title.alternative Eficacia y seguridad de una nueva formulación de enjuague bucal de dexametasona para el manejo de la estomatitis en pacientes con cáncer
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion